Aldeyra Therapeutics Soars 24.9% on Intraday Surge: What's Behind the Volatility?

Summary
• Aldeyra Therapeutics (ALDX) surges 24.86% to $2.26 from an open of $1.855
• Intraday range spans from $1.8245 to $2.32, signaling sharp momentum
• High turnover of 6,311,912 shares with dynamic PE at -4.02
ALDX is making headlines with its intraday surge of nearly 25% in a volatile session. The stock is currently trading well above its 52-week low and has caught the attention of traders and options investors. The pharmaceuticals sector is witnessing mixed news, but Aldeyra's move seems to be driven by independent factors, likely tied to technical momentum or options activity.

Options Flows and Technical Momentum Drive Sharp Rally
Aldeyra Therapeutics' 24.9% intraday move is largely driven by a combination of high-liquidity options activity and technical momentum. The options chain shows heavy buying in front-month calls, particularly in the $2.5 strike expiring on March 27 and the $2.5 strike on April 2, with implied volatility at 30% and turnover volumes above 3,000 for key contracts. The stock is also trading above its 52-week low and is bouncing off the lower Bollinger Band, indicating a potential reversal pattern. RSI at 21.09 and MACD at -0.83 signal oversold conditions, creating a short-term technical backdrop that supports the surge.

Options and Technicals Point to Aggressive Call Plays in ALDX
• MACD: -0.8287 (oversold, negative cross), Signal Line: -0.4369, Histogram: -0.3918 (narrowing divergence)
• RSI: 21.09 (oversold territory, possible bounce)
• Bollinger Bands: Lower band at $1.389, Middle at $4.328, Upper at $7.267 (stock is trading far above lower band)
• 30D MA: $4.639, 100D MA: $4.855, 200D MA: $4.861 (price is below all moving averages, bearish structure)
• Support/Resistance: 30D at $5.44–5.53, 200D at $5.15–5.24 (ALDX is far below key support levels)
• Turnover Rate: 11.34% (elevated for a small-cap stock, indicating active trading)
With ALDX trading near 24.86% above its open, the stock is exhibiting a strong short-term reversal pattern, especially in a bearish context. Traders should watch for a continuation of the rally or a pullback to test the intraday low of $1.82. There is no leveraged ETF for this stock, but high-liquidity options contracts offer leveraged exposure. The two most compelling options from the chain are:

• Contract: ALDX20260417C2.5 (Call), Strike: 2.5, Expiration: 2026-04-17, IV: 138.92%, Delta: 0.47, Theta: -0.0078, Gamma: 0.47, Turnover: 5,025
• IV: 138.92% (extremely high, reflecting high volatility expectations)

• Contract: ALDX20260417C2 (Call), Strike: 2, Expiration: 2026-04-17, IV: 30.00%, Delta: 0.95, Theta: -0.0035, Gamma: 0.55, Turnover: 12,441
• IV: 30.00% (moderate, aligns with typical volatility levels)

Aggressive bulls may consider the ALDX20260417C2.5 for a leveraged play on the bounce, while the ALDX20260417C2 offers a safer, in-the-money position for those expecting a continuation.

Backtest Aldeyra Therapeutics Stock Performance
The backtest of ALDX's performance after a 25% intraday surge from 2022 to the present indicates positive short-to-medium-term gains. The 3-Day win rate is 52.89%, the 10-Day win rate is 55.79%, and the 30-Day win rate is 60.12%, suggesting that the stock tends to perform well in the immediate aftermath of such events. The maximum return during the backtest was 14.19%, which occurred on day 58 after the event, indicating that there is potential for continued upward momentum.

Breakout Play or False Dawn? Watch the Options Activity and Price Action
Aldeyra Therapeutics is on a high-risk/high-reward trajectory, with a 24.86% intraday move fueled by strong options volume and technical indicators pointing to a potential reversal. While the stock is still well below its 52-week high of $6.55, a sustained rally above the $2.32 intraday high could signal a shift in sentiment. For traders, the focus is on the $2.32 level and the 4.328 middle Bollinger Band for potential confirmation. Meanwhile, the sector leader, Pfizer (PFE), is down 0.50%, showing that this rally appears to be a stock-specific move. Investors should monitor the front-month call options and the behavior of the RSI and MACD for signs of strength. A break above $2.35 with rising volume could validate the move as a breakout, but caution is warranted as the stock remains in a bearish trend on longer-term charts.